Lee P - Search Results

1

Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins.

Laurini E, Martinelli V, Lanzicher T, Puzzi L, Borin D, Chen SN, Long CS, Lee P, Mestroni L, Taylor MRG, Sbaizero O, Pricl S. Laurini E, et al. Among authors: lee p. Cardiovasc Res. 2018 May 1;114(6):846-857. doi: 10.1093/cvr/cvy040. Cardiovasc Res. 2018. PMID: 29432544 Free PMC article.

2

Long-Term Efficacy and Safety of ARRY-371797 (PF-07265803) in Patients With Lamin A/C-Related Dilated Cardiomyopathy.

Judge DP, Lakdawala NK, Taylor MRG, Mestroni L, Li H, Oliver C, Angeli FS, Lee PA, MacRae CA. Judge DP, et al. Am J Cardiol. 2022 Nov 15;183:93-98. doi: 10.1016/j.amjcard.2022.08.001. Epub 2022 Sep 13. Am J Cardiol. 2022. PMID: 36114020 Free article.

3

Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study.

MacRae CA, Taylor MRG, Mestroni L, Moses J, Ashley EA, Wheeler MT, Lakdawala NK, Hershberger RE, Sandor V, Saunders ME, Oliver C, Lee PA, Judge DP. MacRae CA, et al. Among authors: lee pa. Circ Genom Precis Med. 2023 Feb;16(1):e003730. doi: 10.1161/CIRCGEN.122.003730. Epub 2022 Dec 14. Circ Genom Precis Med. 2023. PMID: 36515663 Free PMC article. Clinical Trial.

4

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.

Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E. Yeh TC, et al. Clin Cancer Res. 2007 Mar 1;13(5):1576-83. doi: 10.1158/1078-0432.CCR-06-1150. Clin Cancer Res. 2007. PMID: 17332304

5

Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator.

Hinklin RJ, Baer BR, Boyd SA, Chicarelli MD, Condroski KR, DeWolf WE Jr, Fischer J, Frank M, Hingorani GP, Lee PA, Neitzel NA, Pratt SA, Singh A, Sullivan FX, Turner T, Voegtli WC, Wallace EM, Williams L, Aicher TD. Hinklin RJ, et al. Among authors: lee pa. Bioorg Med Chem. 2020 Jan 1;28(1):115232. doi: 10.1016/j.bmc.2019.115232. Epub 2019 Dec 2. Bioorg Med Chem. 2020. PMID: 31818630

6

Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.

Wallace EM, Lyssikatos J, Blake JF, Seo J, Yang HW, Yeh TC, Perrier M, Jarski H, Marsh V, Poch G, Livingston MG, Otten J, Hingorani G, Woessner R, Lee P, Winkler J, Koch K. Wallace EM, et al. Among authors: lee p. J Med Chem. 2006 Jan 26;49(2):441-4. doi: 10.1021/jm050834y. J Med Chem. 2006. PMID: 16420026

7

ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models.

Woessner R, Tunquist B, Lemieux C, Chlipala E, Jackinsky S, Dewolf W Jr, Voegtli W, Cox A, Rana S, Lee P, Walker D. Woessner R, et al. Among authors: lee p. Anticancer Res. 2009 Nov;29(11):4373-80. Anticancer Res. 2009. PMID: 20032381 Free article.

8

Identification of a new class of glucokinase activators through structure-based design.

Hinklin RJ, Boyd SA, Chicarelli MJ, Condroski KR, DeWolf WE Jr, Lee PA, Lee W, Singh A, Thomas L, Voegtli WC, Williams L, Aicher TD. Hinklin RJ, et al. J Med Chem. 2013 Oct 10;56(19):7669-78. doi: 10.1021/jm401116k. Epub 2013 Sep 25. J Med Chem. 2013. PMID: 24015910

9

Prodrug thiamine analogs as inhibitors of the enzyme transketolase.

Le Huerou Y, Gunawardana I, Thomas AA, Boyd SA, de Meese J, Dewolf W, Gonzales SS, Han M, Hayter L, Kaplan T, Lemieux C, Lee P, Pheneger J, Poch G, Romoff TT, Sullivan F, Weiler S, Wright SK, Lin J. Le Huerou Y, et al. Among authors: lee p. Bioorg Med Chem Lett. 2008 Jan 15;18(2):505-8. doi: 10.1016/j.bmcl.2007.11.100. Epub 2007 Dec 3. Bioorg Med Chem Lett. 2008. PMID: 18083562

10

Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models.

Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, Forero-Torres A, Peterson S. Kulukian A, et al. Among authors: lee p. Mol Cancer Ther. 2020 Apr;19(4):976-987. doi: 10.1158/1535-7163.MCT-19-0873. Mol Cancer Ther. 2020. PMID: 32241871

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13,033 results

Search Page